CN116440068A - Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof - Google Patents
Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof Download PDFInfo
- Publication number
- CN116440068A CN116440068A CN202310556095.4A CN202310556095A CN116440068A CN 116440068 A CN116440068 A CN 116440068A CN 202310556095 A CN202310556095 A CN 202310556095A CN 116440068 A CN116440068 A CN 116440068A
- Authority
- CN
- China
- Prior art keywords
- vaginal gel
- gel
- dysbacteriosis
- lactoferrin
- poloxamer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000029 vaginal gel Substances 0.000 title claims abstract description 57
- 229940044950 vaginal gel Drugs 0.000 title claims abstract description 56
- 208000036649 Dysbacteriosis Diseases 0.000 title claims abstract description 20
- 208000027244 Dysbiosis Diseases 0.000 title claims abstract description 20
- 208000009608 Papillomavirus Infections Diseases 0.000 title claims abstract description 20
- 230000007140 dysbiosis Effects 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 6
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims abstract description 45
- 108010063045 Lactoferrin Proteins 0.000 claims abstract description 44
- 102000010445 Lactoferrin Human genes 0.000 claims abstract description 44
- 229940078795 lactoferrin Drugs 0.000 claims abstract description 44
- 235000021242 lactoferrin Nutrition 0.000 claims abstract description 44
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims abstract description 34
- 239000002253 acid Substances 0.000 claims abstract description 28
- 229920001983 poloxamer Polymers 0.000 claims abstract description 22
- 229960000502 poloxamer Drugs 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 239000007853 buffer solution Substances 0.000 claims description 11
- 229920001992 poloxamer 407 Polymers 0.000 claims description 11
- 229940044476 poloxamer 407 Drugs 0.000 claims description 11
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000003906 humectant Substances 0.000 claims description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 229920001993 poloxamer 188 Polymers 0.000 claims 2
- 229940044519 poloxamer 188 Drugs 0.000 claims 2
- 239000004909 Moisturizer Substances 0.000 claims 1
- 230000001333 moisturizer Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 11
- 206010008342 Cervix carcinoma Diseases 0.000 abstract description 10
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 abstract description 10
- 201000010881 cervical cancer Diseases 0.000 abstract description 10
- 241000207202 Gardnerella Species 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 5
- 230000004054 inflammatory process Effects 0.000 abstract description 5
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 210000001215 vagina Anatomy 0.000 abstract description 5
- 241000222122 Candida albicans Species 0.000 abstract description 4
- 229940095731 candida albicans Drugs 0.000 abstract description 4
- 230000003902 lesion Effects 0.000 abstract description 3
- 230000035755 proliferation Effects 0.000 abstract description 3
- 239000000499 gel Substances 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 12
- 102000005348 Neuraminidase Human genes 0.000 description 10
- 108010006232 Neuraminidase Proteins 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 235000011187 glycerol Nutrition 0.000 description 10
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- -1 sialic acid carbohydrates Chemical class 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000341655 Human papillomavirus type 16 Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001879 gelation Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 1
- 208000004926 Bacterial Vaginosis Diseases 0.000 description 1
- VWFCHDSQECPREK-LURJTMIESA-N Cidofovir Chemical compound NC=1C=CN(C[C@@H](CO)OCP(O)(O)=O)C(=O)N=1 VWFCHDSQECPREK-LURJTMIESA-N 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010017730 Gardnerella infections Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 1
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 201000008100 Vaginitis Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000004716 alpha keto acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229960000724 cidofovir Drugs 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000030363 nerve development Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- OESFSXYRSCBAQJ-UHFFFAOYSA-M sodium;3-carboxy-3,5-dihydroxy-5-oxopentanoate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC([O-])=O OESFSXYRSCBAQJ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Reproductive Health (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Oncology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a vaginal gel for preventing and treating HPV infection and dysbacteriosis and a preparation method thereof, wherein the gel is prepared by mixing lactoferrin and polysialic acid and poloxamer, and the vaginal gel has the effects of preventing and treating cervical inflammation, lesions and canceration caused by HPV infection and/or dysbacteriosis; in particular to gardnerella and candida albicans which cause dysbacteriosis of vagina; has the effect of inhibiting proliferation of human cervical cancer cells and has low influence on normal cells.
Description
Technical Field
The invention belongs to the technical field of synthetic biomedical materials, and particularly relates to a vaginal gel for preventing and treating HPV infection and dysbacteriosis and a preparation method thereof.
Background
Human Papilloma Virus (HPV) is continuously infected for a long time, especially high-risk oncogenic viruses such as HPV16, HPV18 and the like, cervical epithelium neoplasia is increased to a certain extent, cervical cancer incidence is also improved, and HPV16 and HPV18 are related to 70% -76% of cervical cancers in the world.
Meanwhile, gardnerella and the like cause cervical inflammation, and are also one of common gynecological cervical lesion diseases. Moreover, researches show that mucopurulent cervicitis caused by conditional pathogenic bacteria such as gardnerella and the like can increase the infection risk of HPV and further increase the occurrence risk of cervical cancer.
HPV infection and gardnerella dysbacteriosis are important factors for cervical cancer, and the condition and the mechanism of the infection are more complicated in clinic. Most of the current medicines are concerned with inhibiting HPV infection or inhibiting bacteria and regulating dysbacteriosis respectively, and few reports on prevention and treatment medicines for the common infection of the two medicines to develop cervical cancer are provided.
Lactoferrin is an 80kDa iron-binding glycoprotein, not only participates in iron transport, but also has powerful biological functions of broad-spectrum antibiosis, antioxidation, anticancer, immune system regulation and the like. Researches show that the lactoferrin is a natural protein in animal colostrum, is a multifunctional protein, has broad-spectrum antibacterial and antiviral infection effects, and can regulate the balance of iron in the body; regulating the generation of bone marrow cells and promoting the growth of the cells; regulating immunity and enhancing disease resistance; inhibiting the action of human tumor cells; can cooperate with various antibiotics and antifungal preparations to treat diseases more effectively. At present, research on prevention and treatment of HPV infection by lactoferrin is more and more, but the function of lactoferrin is single, and further improvement is needed.
Disclosure of Invention
The invention provides a vaginal gel for preventing and treating HPV infection and dysbacteriosis, which has the effects of preventing and treating HPV infection and gardnerella infection, and can greatly reduce the possibility of canceration by combining the prevention and treatment of two infection approaches, thereby providing a healthy environment for female private parts.
A vaginal gel for preventing and treating HPV infection and dysbacteriosis is prepared from lactoferrin and polysialic acid and poloxamer through mixing.
The lactoferrin includes, but is not limited to, one or a combination of lactoferrin, a modified product of lactoferrin, and a derivative of lactoferrin. Wherein the lactoferrin source includes, but is not limited to, mammalian sources, artificial lactoferrin obtained by means of biological fermentation; the lactoferrin, the modified product of the lactoferrin and the derivative of the lactoferrin comprise at least one tryptophan.
The polysialic acid (PSA) is a unique class of linear, homogeneous poly-alpha 2,8 linked sialic acid carbohydrates that are attached to vertebrate nervous system neural adhesion molecules primarily through typical N-linked glycosidic linkages. The hydrolysate is sialic acid, which is alpha-keto acid containing 9 carbons, and has various biological activities such as anti-tumor, anti-inflammatory, antiviral, and nerve development promotion, depending on the existence position and form.
Normally, a large number of pathogenic microorganisms can survive in the vagina, and are mutually dependent and restrained, and a certain amount of pathogenic microorganisms can be kept between the pathogenic microorganisms, so that the pathogenic microorganisms cannot be caused. However, if the organism immunity is low, the ecological balance of the vagina is destroyed, and the dominant pathogenic bacteria are propagated in a large quantity, so that the vagina inflammation is caused. Sialidase levels are an indicator of the evaluation of vaginal environment, produced by gardnerella and anaerobes, and if the values exceed 7IU/ml, bacterial vaginitis can be diagnosed. The sialidase content is thus greatly increased in the vagina suffering from inflammation. Sialidases are capable of hydrolyzing polysialic acid into individual sialic acid molecules.
Polysialic acid carries a large number of negative charges and is capable of electrostatically binding to positively charged lactoferrin; furthermore, polysialic acid is hydrolyzed into single sialic acid molecules under the action of sialidase, lactoferrin and sialic acid are released simultaneously after hydrolysis, the lactoferrin has the effects of resisting bacteria and cancers, and the sialic acid has the effects of resisting tumors, resisting inflammation and resisting viruses.
Because polysialic acid and lactoferrin have high water solubility and are difficult to form gel in water, poloxamer is added. The poloxamer is a block copolymer consisting of Polyoxyethylene (PEO) and polyoxypropylene (PPO), is white particles, and 15% or higher concentration aqueous solution of the poloxamer has the property of reversible thermosensitive gelation, is liquid at low temperature, and forms semisolid transparent gel when heated to above the gelation temperature; the poloxamer composition selected by the invention is flowing liquid at normal temperature and below, and is semisolid gel at the temperature of human body.
Further, the gel may further comprise a humectant such as glycerin, and a preservative such as one or a combination of parabens, sodium benzoate, and benzoic acid.
The beneficial effects are that:
the vaginal gel provided by the invention has the effects of preventing and treating cervical inflammation, lesions and canceration caused by HPV infection and/or dysbacteriosis; in particular to gardnerella and candida albicans which cause dysbacteriosis of vagina; has the effect of inhibiting proliferation of human cervical cancer cells and has low influence on normal cells.
Drawings
Fig. 1 shows the electrophoresis results, M is DNA Marker,500bp,1 is vaginal gel IV incubated in ph=6 enzyme-containing solution for 4h,2 is comparative example 2 (without lactoferrin) vaginal gel incubated in ph=6 enzyme-containing solution for 4h,3 is vaginal gel IV incubated in ph=6 enzyme-free solution for 4h, and 4 is comparative example 1 (without polysialic acid) vaginal gel incubated in ph=6 enzyme-containing solution for 4h.
FIG. 2 is a plot of the trend of fluorescence intensity values in terms of electrophoresis results of vaginal gel IV or comparative example 1 incubated in buffer with or without enzyme for several times.
FIG. 3 is a graph showing the trend of fluorescence intensity values and sialic acid concentration in terms of electrophoresis results of vaginal gel IV incubated in enzyme buffers of different pH values for 4 hours.
Detailed Description
The present invention will be described in further detail with reference to the following examples, which are not intended to limit the invention in any way. Unless specifically stated otherwise, the reagents, methods and apparatus employed in the present invention are those conventional in the art.
The vaginal gel disclosed by the invention is prepared by the following steps:
preparing Tris-HCl buffer solution with pH value of 7-7.5;
respectively dissolving lactoferrin and polysialic acid in a buffer solution, wherein the concentration of the lactoferrin is 150mg/mL, and the concentration of the polysialic acid is 100-200 mg/mL;
mixing lactoferrin buffer solution and polysialic acid buffer solution according to the prescription amount, stirring uniformly, adding poloxamer, stirring uniformly, continuously adding humectant and preservative, stirring uniformly to obtain vaginal gel
The poloxamer is selected from 407 and 188 series, the adding proportion of 407 is 18-20%, and the adding proportion of 188 is 0.5-2%.
The additive comprises 2-10% of lactoferrin, 5-15% of polysialic acid, 0-2% of humectant, 0-0.2% of preservative and the balance of water.
Lactoferrin (derived from cow milk) was purchased from Shanghai derived leaf Biotechnology Co.
Poloxamers, polysialic acid were purchased from sigma aldrich (Shanghai) trade limited.
Example 1
Vaginal gel component I:
poloxamer 407 18%;
poloxamer 108.5%;
lactoferrin 2%;
polysialic acid 8%;
glycerol 2%;
the balance being water.
The gel temperature is: 35 ℃.
Example 2
Vaginal gel II component:
poloxamer 407 19.2%;
poloxamer 108.2%;
lactoferrin 5%;
polysialic acid 8%;
glycerol 2%;
the balance being water.
The gel temperature is: 34 ℃.
Example 3
Vaginal gel III component:
poloxamer 407 19.5%;
poloxamer 108.8%;
lactoferrin 8%;
polysialic acid 8%;
glycerol 2%;
the balance being water.
The gel temperature is: 34 ℃.
Example 4
Vaginal gel IV component:
poloxamer 407 19.5%;
poloxamer 108.5%;
lactoferrin 10%;
polysialic acid 8%;
glycerol 2%;
the balance being water.
The gel temperature is: 33 ℃.
Example 5
Vaginal gel V component:
poloxamer 407 18.7%;
poloxamer 108.5%;
lactoferrin 10%;
polysialic acid 5%;
glycerol 2%;
the balance being water.
The gel temperature is: 35 ℃.
Example 6
Vaginal gel VI component:
poloxamer 407 18.5%;
poloxamer 108.2%;
lactoferrin 10%;
polysialic acid 15%;
glycerol 2%;
the balance being water.
The gel temperature is: 34 ℃.
Example 7
Vaginal gel VII component:
poloxamer 407 19.5%;
poloxamer 108.5%;
lactoferrin 10%;
polysialic acid 8%;
glycerol 2%;
0.2% of nipagin ester;
the balance being water.
The gel temperature is: 33 ℃.
Comparative example 1
Vaginal gel component:
poloxamer 407 18.5%;
poloxamer 108.5%;
lactoferrin 10%;
glycerol 2%;
the balance being water.
The gel temperature is: 35 ℃.
Comparative example 2
Vaginal gel component:
poloxamer 407 18.7%;
poloxamer 108.8%;
polysialic acid 8%;
glycerol 2%;
the balance being water.
The gel temperature is: 35 ℃.
Test example 1
Vaginal gels were tested for in vitro sialic acid and lactoferrin release.
Sialidases (extracted from Clostridium perfringens) were purchased from sigma aldrich (Shanghai) trade limited.
DL500 bp DNA marker is purchased from Takara company; FAM-DNA was purchased from Shanghai Biotechnology Co.
The sialidase solution (200U) was diluted with a buffer system of different pH values in the pH range 4-7, including citrate-sodium citrate buffer (pH 3.0-6.0), phosphate buffer (pH 6.0-8.0). The enzyme solutions with the enzyme activities of 8.5mU, pH=4, pH=5, pH=6 (phosphate buffer solution) and pH=7 are obtained and placed in a constant temperature environment of 40 ℃ for standby.
After 1g of vaginal gel was gelled at 40 ℃, it was poured into 1mL of enzyme solution, and the reaction was continued for several times (0, 1, 2, 4, 8 h) with shaking at constant temperature.
Determining sialic acid content: 20. Mu.L of the reacted supernatant was aspirated and boiled at 100℃for 5min to inactivate the enzymes and lactoferrin. The released sialic acid was detected by thiobarbituric acid (thiobarbituric acid, TBA) method.
Testing lactoferrin content: mu.L of the reacted supernatant was aspirated, 5. Mu.L of FAM-DNA (annealed, 1. Mu. Mol/L in PBS) was added, 1 XPBS buffer was added to a final volume of 20. Mu.L, and the mixture was incubated at 37℃for 20min, followed by gel electrophoresis (Bio-rad vertical electrophoresis apparatus). Adding 3 μl of 6×loading buffer (containing bromophenol blue) into sample to be tested, running at 100V for 35min under electrophoresis parameters of 1×TBE and 10% gel concentration, and measuring protein concentration (y=298.15972x+4730.3143, R 2 =0.9936）。
The vaginal gel 4 prepared in example 1 and the vaginal gel prepared in comparative example 1 without polysialic acid were assayed for in vitro release with or without sialidase by the above method.
Fig. 1 shows the electrophoresis results, M is DNA Marker,500bp,1 is vaginal gel IV incubated in ph=6 enzyme-containing solution for 4h,2 is comparative example 2 (without lactoferrin) vaginal gel incubated in ph=6 enzyme-containing solution for 4h,3 is vaginal gel IV incubated in ph=6 enzyme-free solution for 4h, and 4 is comparative example 1 (without polysialic acid) vaginal gel incubated in ph=6 enzyme-containing solution for 4h.
Fig. 2 is a plot of the trend of fluorescence intensity values converted from the electrophoresis results of vaginal gel IV or comparative example 1 incubated in buffer with or without enzyme for several times (analysis according to analytical software Image lab associated with gel imaging system, select ALEXA488 channel), after extraction of samples at the dry time, the same amount of buffer with or without enzyme was supplemented, ph=6.
FIG. 3 is a graph showing the trend of fluorescence intensity values and sialic acid concentration in terms of electrophoresis results of vaginal gel IV incubated in enzyme buffers of different pH values for 4 hours.
Test example 2
Antibacterial activity test: the antibacterial activity of the gel is determined by using gardnerella and candida albicans as test strains and using a inhibition zone method. The method comprises the following steps: the bacterial solutions are diluted to 1X 10 by PBS buffer solution 7 CFU/mL is evenly coated on an aseptic LB solid agar culture medium, 1g of vaginal gel is completely solidified at 40 ℃, 1mL of sialidase buffer solution (8.5 mU pH=4) is added for mixing and then is subjected to constant-temperature shaking reaction for 4 hours, supernatant liquid is taken to be placed in the center of the culture medium, aerobic bacteria are cultured in an electrothermal constant-temperature incubator at 37 ℃ for 24 hours, anaerobic bacteria are placed in an anaerobic tank firstly and then are placed in the same incubator at 37 ℃ for culturing for 48 hours, and after the culture is completed, a Scan-1200 microbiological technique instrument is used for photographing and measuring the diameter of a bacteriostasis ring. Control 1 was vaginal gel 1 with buffer without sialidase.
Candida albicans (10231) and gardnerella (14018) were purchased from ATCC.
The zone diameters of inhibition for each vaginal gel sample are listed in table 1.
TABLE 1
Test example 3
And (5) testing the activity of the vaginal gel in vitro cervical cancer resisting cells.
The MTT method is adopted to test the inhibition and proliferation effect of the vaginal gel on cervical cancer cells, and the specific method is as follows:
100. Mu.L of cells were concentrated to 1X 10 4 Human cervical cancer cells Hela or human cervical epithelial cells H8 of each mL are inoculated in a 96-well plate and cultured overnight; after 1g of vaginal gel was coagulated completely at 40℃1mL of sialidase was added slowlyAfter mixing the flushing liquid (8.5 mU pH=6) and performing constant temperature shaking reaction for 4 hours, taking supernatant, measuring the concentration of lactoferrin and sialic acid according to the method of test example 1, then using the supernatant to treat cells, adding an equivalent amount of cell culture liquid into a control group, taking cidofovir as a positive control group (the concentration is 80 mg/g), inoculating 5 compound holes at each dose, placing at 37 ℃ and 5% CO 2 After 48h of incubation, detection was performed.
The detection step comprises: adding 10 mu L of 5mg/mL MTT reagent into each hole of the culture plate, continuously culturing for 4 hours, adding 100 mu LDMSO, shaking and uniformly mixing for 10 minutes, testing the OD value by using an enzyme-labeling instrument (lambda=490 nm), and calculating the inhibition ratio according to the formula: inhibition = 1-dosing OD/control OD x 100%.
The inhibition of cancer cells and normal cells by vaginal gel is shown in table 2.
TABLE 2
The above examples are preferred embodiments of the present invention, but the embodiments of the present invention are not limited to the above examples, and any other changes, modifications, substitutions, combinations, and simplifications that do not depart from the spirit and principle of the present invention should be made in the equivalent manner, and the embodiments are included in the protection scope of the present invention.
Claims (8)
1. A vaginal gel for preventing and treating HPV infection and dysbacteriosis, characterized in that the vaginal gel comprises lactoferrin, polysialic acid and poloxamer; the gel temperature of the vaginal gel is within the range of 33-35 ℃, and the vaginal gel is liquid when the gel temperature is lower than the gel temperature.
2. The vaginal gel for preventing and treating HPV infection and dysbacteriosis according to claim 1, wherein the vaginal gel comprises lactoferrin and polysialic acid, poloxamer, moisturizer and preservative.
3. The vaginal gel for preventing and treating HPV infection and dysbacteriosis according to claim 2, wherein poloxamer is 407 and 188, wherein the addition proportion of 407 is 18-20wt% and the addition proportion of 188 is 0.5-2wt%.
4. A vaginal gel for preventing and treating HPV infection and dysbacteriosis according to claim 3, characterized in that it comprises the following components in mass percent: the poloxamer 407 is added in an amount of 18-20%, the poloxamer 188 is added in an amount of 0.5-2%, the lactoferrin is added in an amount of 2-10%, the polysialic acid is added in an amount of 5-15%, the glycerol is added in an amount of 0-2%, the preservative is added in an amount of 0-0.2%, and the balance is water.
5. The vaginal gel for preventing and treating HPV infection and dysbacteriosis according to claim 2, wherein the preparation method of the vaginal gel is as follows:
preparing Tris-HCl buffer solution with pH value of 7-7.5;
respectively dissolving lactoferrin and polysialic acid in a buffer solution, wherein the concentration of the lactoferrin is 150mg/mL, and the concentration of the polysialic acid is 100-200 mg/mL;
mixing lactoferrin buffer solution and polysialic acid buffer solution according to the prescription amount, stirring uniformly, adding poloxamer, stirring uniformly, continuing to add humectant and preservative, and stirring uniformly to obtain the vaginal gel.
6. The vaginal gel for preventing and treating HPV infection and dysbacteriosis according to claim 4, characterized in that it comprises the following components in mass percentage: the poloxamer 407 is added in an amount of 18-20%, the poloxamer 188 is added in an amount of 0.5-2%, the lactoferrin is added in an amount of 10%, the polysialic acid is added in an amount of 8%, the glycerol is added in an amount of 2%, the preservative is added in an amount of 0-0.2%, and the balance is water.
7. The vaginal gel for preventing and treating HPV infection and dysbacteriosis according to any one of claims 1 to 6, wherein the preservative is one or a combination of parabens, sodium benzoate and benzoic acid.
8. The use of a vaginal gel for preventing and treating HPV infection and dysbacteriosis according to any one of claims 1 to 6, wherein the pH environment of the vaginal gel is 4 to 7.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310556095.4A CN116440068B (en) | 2023-05-17 | 2023-05-17 | Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310556095.4A CN116440068B (en) | 2023-05-17 | 2023-05-17 | Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116440068A true CN116440068A (en) | 2023-07-18 |
| CN116440068B CN116440068B (en) | 2023-10-17 |
Family
ID=87120403
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310556095.4A Active CN116440068B (en) | 2023-05-17 | 2023-05-17 | Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116440068B (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011032180A (en) * | 2009-07-30 | 2011-02-17 | Japan Science & Technology Agency | Compound having high affinity to cd22 molecule and enhancing proliferation of b cell |
| CN105031626A (en) * | 2015-08-27 | 2015-11-11 | 南京拉克森生物医药科技有限公司 | Method for preparing charge modified lactoferrin |
| CN105031625A (en) * | 2015-08-27 | 2015-11-11 | 南京拉克森生物医药科技有限公司 | Charge modified lactoferrin and carrageenin combination medicine and preparation method thereof |
| EP2992894A1 (en) * | 2014-09-05 | 2016-03-09 | Progine Farmaceutici Srl | Vaginal formulations for preventing and treating vaginal and cervico-vaginal infections |
| CN107412747A (en) * | 2017-08-24 | 2017-12-01 | 北京亦贝安生物医药科技有限公司 | A kind of compound preparation containing lactoferrin and sialic acid |
| CN112999335A (en) * | 2021-02-26 | 2021-06-22 | 王利琼 | Preparation method of anti-HPV slow-release hydrogel for preventing and treating various gynecological inflammations in female vagina |
| WO2022167925A1 (en) * | 2021-02-04 | 2022-08-11 | Disruptive Technological Advances In Life Science Srl | Association or composition comprising stabilised lactoferrin |
| CN115212298A (en) * | 2022-07-12 | 2022-10-21 | 南京中医药大学 | Vaginal temperature-sensitive composite anti-HPV gel and preparation method and application thereof |
-
2023
- 2023-05-17 CN CN202310556095.4A patent/CN116440068B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011032180A (en) * | 2009-07-30 | 2011-02-17 | Japan Science & Technology Agency | Compound having high affinity to cd22 molecule and enhancing proliferation of b cell |
| EP2992894A1 (en) * | 2014-09-05 | 2016-03-09 | Progine Farmaceutici Srl | Vaginal formulations for preventing and treating vaginal and cervico-vaginal infections |
| CN105031626A (en) * | 2015-08-27 | 2015-11-11 | 南京拉克森生物医药科技有限公司 | Method for preparing charge modified lactoferrin |
| CN105031625A (en) * | 2015-08-27 | 2015-11-11 | 南京拉克森生物医药科技有限公司 | Charge modified lactoferrin and carrageenin combination medicine and preparation method thereof |
| CN107412747A (en) * | 2017-08-24 | 2017-12-01 | 北京亦贝安生物医药科技有限公司 | A kind of compound preparation containing lactoferrin and sialic acid |
| WO2022167925A1 (en) * | 2021-02-04 | 2022-08-11 | Disruptive Technological Advances In Life Science Srl | Association or composition comprising stabilised lactoferrin |
| CN112999335A (en) * | 2021-02-26 | 2021-06-22 | 王利琼 | Preparation method of anti-HPV slow-release hydrogel for preventing and treating various gynecological inflammations in female vagina |
| CN115212298A (en) * | 2022-07-12 | 2022-10-21 | 南京中医药大学 | Vaginal temperature-sensitive composite anti-HPV gel and preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| ANDREA KÜHNLE ET AL.: "Polysialic acid interacts with lactoferrin and supports its activity to inhibit the release of neutrophil extracellular traps", CARBOHYDR POLYM ., no. 208, pages 32 - 41 * |
| 李文烨: "重组腺病毒介导的人乳铁蛋白抗宫颈癌作用及其机理研究", 中国博士学位论文全文数据库 医药卫生科技辑, no. 6, pages 072 - 80 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116440068B (en) | 2023-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Magnusson et al. | Preparation of purified tuberculin RT 23 | |
| Cockerell et al. | Clinical, histologic, microbiologic, and biochemical characterization of the causative agent of bacillary (epithelioid) angiomatosis: a rickettsial illness with features of bartonellosis | |
| Wang et al. | Exopolysaccharide, isolated from a novel strain Bifidobacterium breve lw01 possess an anticancer effect on head and neck cancer–genetic and biochemical evidences | |
| JPH0789950B2 (en) | Method for producing protein having immunological cross-reactivity with diphtheria toxin | |
| WO2022222259A1 (en) | Lactobacillus reuteri having improved anti-aging and hair health enhancement effects, and application thereof | |
| CN113122453A (en) | Culture medium for separating brucella in woodchuck tissue and preparation method thereof | |
| Douraghi et al. | Comparative evaluation of three supplements for Helicobacter pylori growth in liquid culture | |
| CN114891677A (en) | Separation and application of strain with anticancer effect | |
| CN116440068B (en) | Vaginal gel for preventing and treating HPV infection and dysbacteriosis and preparation method thereof | |
| CN111500499B (en) | Application of osteopontin in adjusting flora structure in-vitro culture process of intestinal flora | |
| Ali et al. | Evaluation of siderophore produced by different clinical isolate Pseudomonas aeruginosa | |
| JP5410708B2 (en) | Microorganisms and microorganism preparations belonging to the genus Sharpea, and oral compositions | |
| CN114525218B (en) | Bifidobacterium longum, culture method thereof and application of bifidobacterium longum in high-yield gamma-aminobutyric acid and 5-hydroxytryptamine | |
| CN113512559B (en) | Mycoplasma bovis Mbov _0701 mutant gene and mutant strain and application thereof | |
| Soldo | Cultivation of two strains of killer Paramecium aurelia in axenic medium. | |
| CN114657082B (en) | Lactococcus lactis and application thereof | |
| AU2020103625A4 (en) | Applications of bacillus calmette-guerin (bcg) polysaccharide and nucleic acid in in-vitro culture of cytokine-induced-killer (cik) cells and preparation of antitumor drugs | |
| CN109874329A (en) | A kind of production butyric acid is dwelt bacillus faecalis and its cultural method and application | |
| CN113621572A (en) | Application of lactobacillus rhamnosus in adhering colon cells | |
| CN105776574A (en) | Microbial flocculant and application thereof in slaughter wastewater treatment | |
| Buchanan-Davidson et al. | Action of synthetic polylysine on the growth and phagocytosis of bacteria in vitro | |
| CN112063566A (en) | Enterococcus faecium and application thereof | |
| RU2247775C1 (en) | Liquid nutrient transporting medium for collection, culturing and transportation of patient blood with suspicion for brucellosis | |
| KR19990063833A (en) | Helicobacter pylori protein | |
| CN117264853B (en) | Screening method and application of selenium-enriched animal bifidobacterium H15 for relieving ulcerative colitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20230920 Address after: Floors 1-4, building 22, No. 20, Xiushui Road, pharmaceutical high tech Zone, Taizhou, Jiangsu 225300 Applicant after: Jiangsu Hengrui Biomedical Technology Co.,Ltd. Address before: 225300 Building 9, north of Chuangye Avenue, Gaogang science and Technology Innovation Park, Gaogang District, Taizhou City, Jiangsu Province Applicant before: Pudite (Taizhou) Biotechnology Co.,Ltd. |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |